From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability
Expert Opinion on Drug Safety, Ahead of Print. (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 11, 2015 Category: Drugs & Pharmacology Tags: article Source Type: research
Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients.
CONCLUSIONS: The levels of MMP-2 and -9 in aqueous of glaucomatous eyes on topical prostaglandin analogues were the same as those of normal age-matched control patients. This could reflect either a return to normal levels with efficacious treatment or a lack of difference between disease and nondisease states.
PMID: 25677276 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - February 1, 2015 Category: Opthalmology Authors: Pradhan ZS, Dalvi RA, Lai T, Kranemann C, Boyd S, Birt CM Tags: Can J Ophthalmol Source Type: research
Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timolol fixed combinations in patients with normal-tension glaucoma.
Conclusions. Switching from PG monotherapy to PG/b fixed combination therapy for NTG resulted in a greater intraocular pressure reduction than PG alone without increasing the number of instillations.
PMID: 25505978 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - December 18, 2014 Category: Opthalmology Tags: J Ophthalmol Source Type: research
Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
Background:
Medications to control intraocular pressure (IOP) are frequently preserved using benzalkonium chloride (BAK), which can negatively affect the ocular surface. Data are needed to assess efficacy and safety of prostaglandin drugs preserved with and without BAK. The present study compared the efficacy and safety of BAK-free travoprost 0.004% (TRAV) and BAK 0.02%-preserved bimatoprost 0.01% (BIM) during late-day time points in patients with open-angle glaucoma or ocular hypertension.
Methods:
This was a 12-week, phase 4, randomized, investigator-masked, crossover study. 84 patients with IOP >=24 and (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - November 28, 2014 Category: Opthalmology Authors: Harvey DuBinerDouglas Hubatsch Source Type: research
Accidental Overdose of Travoprost
ConclusionsBecause of the few systemic adverse effects, prostaglandin analogs are widely used for the treatment of glaucoma. Travoprost should be taken once daily; therefore, overdose is extremely uncommon. Systemic prostaglandins have been found to be mediators of uterine activity and are used to induce labor and terminate pregnancies. The high dose of this topical medication, as well as the compromised cornea, makes this case unique. The unusual circumstances observed in this case greatly expand our knowledge regarding the potential adverse effects of travoprost. (Source: Optometry and Vision Science)
Source: Optometry and Vision Science - November 21, 2014 Category: Opthalmology Tags: CLINICAL COMMUNICATIONS: Clinical Cases Source Type: research
Impact of Combination Use of 0.004% Travoprost and 2% Pilocarpine on Matrix Metalloproteinases Synthesized by Rabbit Ciliary Muscle: a Pilot Study
Conclusions Pilocarpine has little effect on activity of MMP1/2. Travoprost can increase activity of MMP1/2 gradually. Activity of MMP1/2 is rapidly increased by pilocarpine combined with travoprost, but shows small change with the prolonged treatment. (Source: Chinese Medical Sciences Journal)
Source: Chinese Medical Sciences Journal - November 1, 2014 Category: Journals (General) Source Type: research
A Prospective Pharmacoeconomic Study of Bilateral Prostaglandin/ Prostamide Therapy for Lowering Intraocular Pressure (Iop) in the Patients in South India
To determine monthly cost and cost effectiveness of bilateral prostaglandin/ prostamide therapy for lowering intraocular pressure (IOP) in patients taking bimatoprost (0.03%), latanoprost (0.005%), or travoprost (0.004%). (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: D. Addanki Source Type: research
Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews.
Conclusion. No high quality evidence on relative efficacy and tolerability of the most commonly used mono-compound IOP-lowering drugs for POAG/OHT exists. Moderate quality evidence indicates latanoprost as a treatment with the most favorable trade-off between benefits and harms.
PMID: 25358880 [PubMed - in process] (Source: Croatian Medical Journal)
Source: Croatian Medical Journal - October 30, 2014 Category: Journals (General) Authors: Daka Q, Trkulja V Tags: Croat Med J Source Type: research
The Effect of Preservatives and Antiglaucoma Treatments on the Ocular Surface of Mice With Dry Eye [Cornea]
Conclusions.
This study indicated that use of BAK has negative effects on the ocular surface under normal and dry eye conditions, even if the association with bimatoprost does not confirm the same results. A BAK-free travoprost preparation showed positive effects on tear secretion and corneal protection. (Source: Investigative Ophthalmology)
Source: Investigative Ophthalmology - October 14, 2014 Category: Opthalmology Authors: Barabino, S., Antonelli, S., Cimbolini, N., Mauro, V., Bouzin, M. Tags: Cornea Source Type: research
Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-based Prospective Randomized Study
Purpose:To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.
Methods:Patients with primary open angle glaucoma were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measure was the mean change in IOP from baseline at each visit. Secondary outcome measures included the incidence of adverse events.
Results:Eighty patients (80 eyes) were included finally: 40 eyes in each group. Baseline mean IOPs were 24.78±3.53 and 25.26±3.51 mm...
Source: Journal of Glaucoma - October 1, 2014 Category: Opthalmology Tags: Original Studies Source Type: research
Long-term 24-hour Intraocular Pressure Control With Travoprost Monotherapy in Patients With Primary Open-angle Glaucoma
Conclusions:The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - October 1, 2014 Category: Opthalmology Tags: Original Studies Source Type: research
Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
Conclusions: Preservatives included in the anti-glaucoma eye-drops showed different ocular surface changes according to the concentration and type in the rabbits. Prostaglandin analogues preserved with higher level of BAK may cause more harmful effects on the ocular surface than PQ-preserved medications.
PMID: 25265260 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - September 29, 2014 Category: Toxicology Authors: Lee HJ, Jun RM, Cho MS, Choi KR Tags: Cutan Ocul Toxicol Source Type: research
Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma
To evaluate the intraocular pressure (IOP) lowering effect of 2 trabecular microbypass stents and postoperative travoprost in patients with open-angle glaucoma (OAG) not controlled on 2 medications preoperatively. (Source: Journal of Cataract and Refractive Surgery)
Source: Journal of Cataract and Refractive Surgery - August 1, 2014 Category: Opthalmology Authors: Iqbal Ike K. Ahmed, L. Jay Katz, David F. Chang, Eric D. Donnenfeld, Kerry D. Solomon, Lilit Voskanyan, Thomas W. Samuelson Tags: Reviews/Articles Source Type: research
Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma.
CONCLUSIONS:: Travoprost and bimatoprost are superior in IOP control than latanoprost, but latanoprost is better tolerated in patients with CACG.
PMID: 25044139 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 8, 2014 Category: Opthalmology Authors: Li J, Lin X, Yu M Tags: Eur J Ophthalmol Source Type: research
24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost.
CONCLUSION: The mean 24-h IOP lowering of TTFC was statistically more significant compared to LTFC in patients insufficiently controlled with latanoprost monotherapy. Measurement of ocular surface health and tear film status favored the BAK-free TTFC compared to LTFC.
PMID: 24919410 [PubMed - as supplied by publisher] (Source: Advances in Therapy)
Source: Advances in Therapy - June 12, 2014 Category: Drugs & Pharmacology Authors: Konstas AG, Voudouragkaki IC, Boboridis KG, Haidich AB, Paschalinou E, Giannopoulos T, Dragoumis ND, Makridis AK, Kahook MY Tags: Adv Ther Source Type: research
